Reviva Pharmaceuticals Holdings (RVPH) Short term Debt (2023 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Short term Debt of $231274.0 for Q1 2026, down 43.16% sequentially from $406875.0 in Q4 2025, and up 3.11% YoY from $224300.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Short term Debt (2023 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Short term Debt for 4 years, with the latest figure at $231274.0 in Q1 2026.
- Quarterly Short term Debt rose 3.11% year-over-year to $231274.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231274.0 (up 3.11% YoY) and the FY2025 annual result came in at $406875.0, down 11.19% from the prior year.
- Short term Debt slipped to $231274.0 in Q1 2026 per RVPH's latest filing, from $406875.0 in the prior quarter.
- Over five years, Short term Debt peaked at $667500.0 in Q1 2023 and troughed at $83000.0 in Q3 2024.
- A 4-year average of $288077.2 and a median of $224300.0 in 2025 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2024 and 2026: Short term Debt plunged 62.7% in 2024, then rose 3.11% in 2026.
- Over 4 years, Short term Debt stood at $222500.0 in 2023, then surged by 105.91% to $458154.0 in 2024, then dropped by 11.19% to $406875.0 in 2025, then sank by 43.16% to $231274.0 in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $231274.0, $406875.0, and $113246.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144,093.00 |
| Mar 31, 2026 | 231,274.00 |
| Dec 31, 2025 | 406,875.00 |
| Jun 30, 2025 | 113,246.00 |
| Mar 31, 2025 | 224,300.00 |
| Dec 31, 2024 | 458,154.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 207,500.00 |
| Mar 31, 2024 | 332,000.00 |
| Sep 30, 2023 | 222,500.00 |
| Jun 30, 2023 | 222,500.00 |
| Mar 31, 2023 | 667,500.00 |